Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726869 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
A Phase 1 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00726869 is a Phase 1 study that was terminated before completion, run by Abbott. The registered enrollment target is 28 participants.
The verdict
NCT00726869, a Phase 1 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This Phase 1/2, multi-center, open-label, multiple-dose, dose escalation study will evaluate the combination of elotuzumab and bortezomib in subjects with MM following 1 to 3 prior therapies. For the Phase 1 portion, elotuzumab will be administered by intravenous (IV) infusion at up to 4 dose levels ranging from 2.5 mg/kg to 20.0 mg/kg within 30 minutes following the administration of bortezomib at 1.3 mg/m\^2 IV bolus. Bortezomib will be given in 21 day cycles (twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest period). Elotuzumab will be administered as a separate infusion within 30 minutes following bortezomib administration on the same days as the first and last dose of each bortezomib cycle (i.e., Days 1 and 11).
Interventions
- DRUG Elotuzumab (HuLuc63)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726869
The ClinicalTrials.gov registry entry for NCT00726869 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elotuzumab (HuLuc63) is the first listed.
NCT00726869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726869 about?
NCT00726869 is a clinical study titled "A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.". This Phase 1/2, multi-center, open-label, multiple-dose, dose escalation study will evaluate the combination of elotuzumab and bortezomib in subjects with MM following 1 to 3 prior therapies. For the Phase 1 portion, elotuzumab will be administered by intravenous (IV) infusion at up to 4 dose levels...
What is the current status of trial NCT00726869?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2008-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00726869?
The interventions under investigation include: Elotuzumab (HuLuc63) (DRUG).
Who is sponsoring clinical trial NCT00726869?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.